Increased CD38 expression is associated with favorable prognosis in adult acute leukemia

Leuk Res. 2000 Feb;24(2):153-9. doi: 10.1016/s0145-2126(99)00147-2.

Abstract

CD38 is expressed in acute lymphoblastic leukemia (ALL) and acute myelogenous leukemia (AML) blasts and its prognostic significance is unknown. We investigated CD38 expression in 304 AML and 138 ALL patients. CD38 was lower in AML-M3 compared to other FAB subtypes (5% vs. 41%; P < 0.001), but was similar among ALL subtypes (56.6%; P = 0.69). Ph + ALL and AML with t(15; 17) patients showed lower CD38 expression than the other cytogenetic groups. Overall survival favored AML and ALL patients with higher CD38 levels. Multivariate analysis revealed CD38 expression to be an independent outcome predictor in AML, but not in ALL.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • ADP-ribosyl Cyclase
  • ADP-ribosyl Cyclase 1
  • Acute Disease
  • Adult
  • Antigens, CD*
  • Antigens, Differentiation / immunology*
  • Humans
  • Immunophenotyping
  • Karyotyping
  • Leukemia, Myeloid / genetics
  • Leukemia, Myeloid / immunology*
  • Membrane Glycoproteins
  • Middle Aged
  • Multivariate Analysis
  • NAD+ Nucleosidase / immunology*
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology*
  • Prognosis
  • Survival Analysis

Substances

  • Antigens, CD
  • Antigens, Differentiation
  • Membrane Glycoproteins
  • ADP-ribosyl Cyclase
  • CD38 protein, human
  • NAD+ Nucleosidase
  • ADP-ribosyl Cyclase 1